Valuation: SpringWorks Therapeutics, Inc.

Market Cap 3.54B 3.07B 2.86B 2.63B 4.96B 337B 5.02B 33.59B 13.18B 168B 13.3B 13B 558B P/E 2023
-7.09x
P/E 2024 -10.4x
Enterprise Value 3.09B 2.67B 2.49B 2.29B 4.33B 293B 4.38B 29.28B 11.49B 147B 11.59B 11.34B 486B EV / Sales 2023
362,507,725x
EV / Sales 2024 11,654,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
81.77
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap.
1/7/25 Issuer sale

Director

85,011 0.1134%
1/7/25 Issuer sale

Chief Financial Officer

738,955 0.9861%
1/7/25 Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%-.--%+85.00% 3.54B
+1.04%+10.52%+34.86%+0.28% 76.75B
+0.13%+5.76%+25.55%+187.16% 50.46B
+1.02%+0.81%-7.73%+21.83% 48.5B
+1.30%+3.46%-50.91%-49.51% 44.14B
-0.87%-1.24%+55.49%-23.16% 30.53B
-0.66%-5.74%+54.13%+88.28% 24.28B
-1.29%+3.24%+104.79%-48.00% 22.46B
+0.72%+3.23%-7.24%+213.08% 20.04B
-0.10%-1.86%+66.61%+162.37% 16.03B
Average +0.56%-0.34%+27.56%+63.73% 33.67B
Weighted average by Cap. +0.68%+0.67%+22.65%+47.13%

Financials

2023 2024
Net sales 5.45 4.72 4.4 4.04 7.64 517.94 7.72 51.68 20.28 259.15 20.46 20.01 858.28 191.59 165.94 154.68 142.27 268.58 18.22K 271.58 1.82K 713.42 9.12K 719.57 703.71 30.19K
Net income -325M -282M -262M -241M -456M -30.91B -461M -3.08B -1.21B -15.47B -1.22B -1.19B -51.23B -258M -224M -208M -192M -362M -24.54B -366M -2.45B -961M -12.28B -969M -948M -40.67B
Net Debt -656M -568M -529M -487M -919M -62.33B -929M -6.22B -2.44B -31.19B -2.46B -2.41B -103B -454M -393M -367M -337M -636M -43.17B -644M -4.31B -1.69B -21.6B -1.71B -1.67B -71.54B
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock